The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Armlupeg is indicated for decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
Diversifying its portfolio to include late-phase antiviral agent
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Subscribe To Our Newsletter & Stay Updated
